{"id":3789,"date":"2017-09-19T10:32:15","date_gmt":"2017-09-19T01:32:15","guid":{"rendered":"https:\/\/hcv1004zroqo.smartrelease.jp\/mg\/?page_id=3789"},"modified":"2019-01-16T10:41:18","modified_gmt":"2019-01-16T01:41:18","slug":"transparency_guidelines","status":"publish","type":"page","link":"https:\/\/www.ominedo.co.jp\/en\/company\/transparency_guidelines\/","title":{"rendered":"About transparency guidelines"},"content":{"rendered":"

Transparency guidelines for the relationship between company activities and medical
\ninstitutions, etc.<\/h2>\n

Ominedo Pharmaceutical Industry Co., Ltd. (hereinafter called \u201cthe Company\u201d)
\nestablished the \u201cTransparency guidelines for the relationship between company
\nactivities and medical institutions, etc.\u201d as follows in order to ensure the transparency
\nof relationships with medical institutions, etc. in all stages from research and
\ndevelopment of medical medicines to the manufacture and sales of products and to obtain a
\nbroad understanding that our company\u2019s activities are conducted upon securing high
\nethical standards.<\/p>\n

1. Method and timing of disclosure
\nThe Company will disclose via the Company website the funding that is to be disclosed
\nfor the target year (October to September) after the settlement is finalized.<\/h3>\n

 <\/p>\n

2. Target for disclosure
\nThe details are listed in each guidance.<\/h3>\n

\u25c6Ethical medicines
\n\u30fbClick here for the details of Transparency guidelines (ethical medicines)<\/a>
\n\u30fbViewing public information (Display the terms of use)<\/a><\/p>\n

\u25c6OTC medicines
\n\u30fbClick here for the details of Transparency guidelines (OTC medicines)<\/a>
\n\u30fbViewing public information (Display the terms of use)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Transparency guidelines for the relationship between company activities and medical institutions, etc. Ominedo Pharmaceutical Industry Co., Ltd. (hereinafter called \u201cthe Company\u201d) established the \u201cTransparency guidelines for the relationship between company activities and medical institutions, etc.\u201d as follows in order to ensure the transparency of relationships with medical institutions, etc. in all stages from research and development of medical medicines to the manufacture and sales of products and to obtain a broad understanding that our company\u2019s activities are conducted upon securing high ethical standards. 1. Method and timing of disclosure The Company will disclose via the Company website the funding that is to be disclosed for the target year (October to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3770,"menu_order":26,"comment_status":"open","ping_status":"open","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-3789","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/pages\/3789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/comments?post=3789"}],"version-history":[{"count":7,"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/pages\/3789\/revisions"}],"predecessor-version":[{"id":4122,"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/pages\/3789\/revisions\/4122"}],"up":[{"embeddable":true,"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/pages\/3770"}],"wp:attachment":[{"href":"https:\/\/www.ominedo.co.jp\/en\/wp-json\/wp\/v2\/media?parent=3789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}